A First-in-Human Study of the Bioheart Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease: Two-Year Clinical and Imaging Outcomes.

Abstract

INTRODUCTION:

Newer generation bioresorbable scaffolds (BRSs) with thinner struts and improved deliverability are expected to enhance safety and efficacy profiles. Bioheart (Bio-Heart, Shanghai, China) BRS is constructed from a PLLA (poly-l-lactic acid) backbone coated with a PDLLA (poly D-l-lactic acid) layer eluting sirolimus. We report 2-year serial intracoronary imaging findings.

METHODS:

In this first-in-human study, 46 patients with single de novo lesions in native coronary vessels (vessel size 3.0-3.75 mm, lesion length ≤ 25 mm) were enrolled at a single institution. Baseline intravascular ultrasound (IVUS) and post-implantation IVUS and optical coherence tomography (OCT) examinations were mandatory. After successful implantations of BRS, the 46 patients were randomized to two different follow-up cohorts in a 2:1 ratio. Thirty patients in cohort 1 had to undergo angiography, IVUS, and OCT follow-ups at 6 and 24 months, respectively. The 16 patients in cohort 2 underwent the same types of imaging follow-ups at 12 and 36 months, respectively. Clinical follow-ups were scheduled uniformly in both cohorts at 1, 6, and 12 months and annually up to 5 years for all patients.

RESULTS:

Between August and November 2016, a total of 54 patients were assessed. However, 8 patients could not meet all the inclusion criteria; thus, the remaining 46 patients (age 57.5 ± 8.7 years, 34.8% female, 50.0% with unstable angina, 26.1% diabetics) with 46 target lesions were enrolled in this study. All patients in both cohorts were required to complete clinical follow-up uniformly and regularly. In cohort 1, one patient had definite scaffold thrombosis within 6 months of follow-up; thus, after 6 months, cohort 1 had 96.7% patients . Imaging follow-up was available in 24 patients, and in-scaffold late loss was 0.44 ± 0.47 mm; intracoronary imaging confirmed the late loss was mainly due to to neointimal hyperplasia, but not scaffold recoil.

CONCLUSIONS:

Serial 2-year clinical and imaging follow-up results confirmed the preliminary safety and efficacy of Bioheart BRS for treatment of simple coronary lesions.

• Authors: Md Misbahul Ferdous, Zhao Jie, Lijian Gao, Shubin Qiao, Haibo Liu, Changdong Guan, Fenghuan Hu, Lakshme Kottu, Jie Qian, Hongbin Yan, Tong Luo, Weixian Yang, Hong Qiu, Yi Mao, Zhongwei Sun, Mengyue Yu, Jingang Cui, Bo Xu, Yongjian Wu
• Journal: Advances in therapy (Adv Ther) Vol. 39 Issue 8 Pg. 3749-3765 (08 2022) ISSN: 1865-8652 [Electronic] United States
• PMID: 35768708 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: © 2022. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature.

Chemical References

• Cardiovascular Agents
• Sirolimus

Topics

• Absorbable Implants
• Aged
• Cardiovascular Agents (therapeutic use)
• China
• Coronary Angiography
• Coronary Artery Disease (diagnostic imaging, surgery)
• Drug-Eluting Stents
• Female
• Humans
• Male
• Middle Aged
• Percutaneous Coronary Intervention
• Prosthesis Design
• Sirolimus (therapeutic use)
• Tomography, Optical Coherence
• Treatment Outcome